Maxine Sun

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5801779/publications.pdf

Version: 2024-02-01

100 papers	5,352 citations	101543 36 h-index	91884 69 g-index
101 all docs	101 docs citations	101 times ranked	7020 citing authors

#	Article	IF	Citations
1	Epidemiology of Renal Cell Carcinoma. European Urology, 2019, 75, 74-84.	1.9	917
2	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	30.7	488
3	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell, 2021, 39, 649-661.e5.	16.8	263
4	Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis. European Urology, 2011, 59, 135-141.	1.9	259
5	Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 3939-3947.	1.6	246
6	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	16.8	230
7	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. Journal of Clinical Oncology, 2016, 34, 3267-3275.	1.6	185
8	Neoadjuvant chemotherapy prior to radical cystectomy for muscleâ€invasive bladder cancer with variant histology. Cancer, 2017, 123, 4346-4355.	4.1	138
9	The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. European Urology, 2017, 72, 14-19.	1.9	128
10	Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. European Urology, 2014, 65, 235-241.	1.9	110
11	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	1.9	110
12	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	1.6	104
13	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology, 2016, 2, 500.	7.1	94
14	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	12.8	84
15	Contemporary incidence and mortality rates of kidney cancer in the United States. Canadian Urological Association Journal, 2014, 8, 247.	0.6	78
16	Adjuvant Vascular Endothelial Growth Factorâ€“targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European Urology, 2018, 74, 611-620.	1.9	77
17	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€“Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	1.6	70
18	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2018, 199, 1417-1425.	0.4	70

#	Article	IF	Citations
19	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Preventive Medicine, 2016, 89, 140-145.	3.4	63
20	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
21	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	1.9	62
22	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2018, 4, 225.	7.1	58
23	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Advances, 2020, 4, 2430-2438.	5.2	54
24	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 125-136.	3.9	53
25	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	1.6	52
26	In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy. European Urology, 2013, 63, 1107-1114.	1.9	51
27	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Current Urology Reports, 2017, 18, 15.	2.2	49
28	Complications After Metastasectomy for Renal Cell Carcinomaâ€”A Population-based Assessment. European Urology, 2017, 72, 171-174.	1.9	44
29	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. European Urology Focus, 2019, 5, 474-481.	3.1	44
30	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 293.e1-293.e10.	1.6	43
31	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. European Urology, 2018, 73, 445-451.	1.9	43
32	Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. European Urology Focus, 2019, 5, 77-80.	3.1	43
33	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. Journal of Urology, 2016, 196, 1090-1095.	0.4	42
34	The association of hypoalbuminemia with early perioperative outcomes â€“ A comprehensive assessment across 16 major procedures. American Journal of Surgery, 2017, 214, 871-883.	1.8	42
35	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	1.9	40
36	Variation in the use of active surveillance for lowâ€risk prostate cancer. Cancer, 2018, 124, 55-64.	4.1	40

#	Article	IF	Citations
37	Testosterone Replacement Therapy Following the Diagnosis of Prostate Cancer: Outcomes and Utilization Trends. Journal of Sexual Medicine, 2014, 11, 1063-1070.	0.6	39
38	Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations. JAMA Internal Medicine, 2016, 176, 546.	5.1	32
39	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. European Journal of Surgical Oncology, 2018, 44, 1439-1445.	1.0	32
40	A Surveillance, Epidemiology and End Results (<scp>SEER</scp>) database malfunction: perceptions, pitfalls and verities. BJU International, 2016, 117, 551-552.	2.5	31
41	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. Journal of Urology, 2017, 198, 1061-1068.	0.4	31
42	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2018, 200, 573-581.	0.4	31
43	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. Journal of Urology, 2019, 201, 735-741.	0.4	31
44	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clinical Genitourinary Cancer, 2021, 19, e92-e99.	1.9	30
45	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. European Urology Oncology, 2021, 4, 396-404.	5.4	30
46	The influence of physician recommendation on prostate-specific antigen screening. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 424.e1-424.e7.	1.6	28
47	An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program. Urology, 2017, 103, 91-98.	1.0	27
48	Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU International, 2018, 121, 811-818.	2.5	27
49	Doseâ€dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International, 2016, 118, 221-229.	2.5	22
50	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	1.6	21
51	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1049-1058.	4.9	21
52	Reassessing the value of highâ€volume cancer care in the era of precision medicine. Cancer, 2018, 124, 1319-1321.	4.1	20
53	Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act. JAMA Oncology, 2018, 4, 128.	7.1	20
54	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Annals of Surgical Oncology, 2019, 26, 297-305.	1.5	20

#	Article	IF	Citations
55	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome raceâ€based differences in survival?. Cancer, 2019, 125, 1319-1329.	4.1	20
56	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. European Urology Oncology, 2021, 4, 66-72.	5.4	20
57	External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. Journal of Urology, 2016, 195, 283-289.	0.4	19
58	Accountable care organizations and the use of cancer screening. Preventive Medicine, 2017, 101, 15-17.	3.4	18
59	Pediatric Nephrectomy: Incidence, Indications and Use of Minimally Invasive Techniques. Journal of Urology, 2014, 191, 764-770.	0.4	17
60	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e129-e139.	1.9	17
61	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 410-418.	3.9	17
62	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 78.e13-78.e19.	1.6	16
63	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. JMIR MHealth and UHealth, 2020, 8, e20224.	3.7	14
64	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	2.2	12
65	Population-based Comparative Effectiveness of Salvage Radical Prostatectomy vs Cryotherapy. Urology, 2014, 83, 653-657.	1.0	11
66	Recurrence in renal cell carcinoma: the work is not done. Nature Reviews Urology, 2016, 13, 246-247.	3.8	11
67	Lower odds of cardiac events for gonadotrophinâ€releasing hormone antagonists versus agonists. BJU International, 2020, 126, 9-10.	2.5	11
68	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREÂ® Military Database. Journal of Urology, 2017, 198, 1295-1300.	0.4	10
69	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clinical Cancer Research, 2022, 28, 748-755.	7.0	9
70	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. Journal of Oncology Practice, 2019, 15, e547-e559.	2.5	8
71	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	3.9	8
72	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 413-418.	1.3	8

#	Article	IF	Citations
73	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. European Urology Focus, 2016, 2, 3-9.	3.1	7
74	State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. Urology, 2018, 112, 56-65.	1.0	7
75	Association of Affordable Care Act-related Medicaid expansion with variation in utilization of surgical services. American Journal of Surgery, 2020, 220, 441-447.	1.8	7
76	Association of Androgen Deprivation Therapy With Alzheimerâ€™s Disease: Unmeasured Confounders. Journal of Clinical Oncology, 2016, 34, 2801-2803.	1.6	6
77	Risk Assessment in Small Renal Masses. Urologic Clinics of North America, 2017, 44, 189-202.	1.8	6
78	Comparative effectiveness research methodology using secondary data: A starting userâ€™s guide. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 174-182.	1.6	6
79	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	5.4	6
80	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 74.e13-74.e20.	1.6	6
81	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States. JAMA Oncology, 2016, 2, 543.	7.1	5
82	Assessing robot-assisted laparoscopic prostatectomy. Lancet, The, 2017, 389, 799.	13.7	5
83	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 130.e17-130.e24.	1.6	4
84	Statistical Analysis Plans in Observational Research. JAMA - Journal of the American Medical Association, 2013, 309, 32.	7.4	3
85	Re: Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. European Urology, 2016, 69, 963-964.	1.9	2
86	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.6	2
87	Prostate cancer management costs vary by disease stage at presentation. Prostate Cancer and Prostatic Diseases, 2020, 23, 564-566.	3.9	2
88	Comparative Effectiveness of Transurethral Resection Techniques in the Inpatient Setting for Benign Prostatic Hyperplasia. Urology Practice, 2018, 5, 377-382.	0.5	1
89	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 400.e15-400.e22.	1.6	1
90	Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction. European Urology, 2016, 69, 92-93.	1.9	0

#	Article	IF	Citations
91	Reply to C. Buttigliero et al and B. Biswas et al. Journal of Clinical Oncology, 2017, 35, 1266-1267.	1.6	0
92	Assessment of metastasectomy complications in renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 619-619.	1.6	0
93	Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report.. Journal of Clinical Oncology, 2016, 34, 450-450.	1.6	0
94	Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival.. Journal of Clinical Oncology, 2016, 34, 620-620.	1.6	0
95	The adverse effects of androgen-deprivation therapy: Comparison between gonadotropin-releasing hormone agonists and orchiectomy in the SEER-Medicare population.. Journal of Clinical Oncology, 2016, 34, 304-304.	1.6	0
96	Adverse effects of androgen deprivation therapy on cognitive impairment for men with prostate cancer: A meta-analysis.. Journal of Clinical Oncology, 2017, 35, e16506-e16506.	1.6	0
97	Accountable care organizations and the use of prostate cancer screening and breast cancer screening.. Journal of Clinical Oncology, 2017, 35, e18308-e18308.	1.6	0
98	The impact of treatment at minority-serving hospitals on outcomes for bladder cancer.. Journal of Clinical Oncology, 2018, 36, 492-492.	1.6	0
99	Do accountable care organizations impact prostate cancer screening?. Journal of Clinical Oncology, 2018, 36, 6546-6546.	1.6	0
100	Do accountable care organizations impact prevalence of mammography and colonoscopies among Medicare beneficiaries?. Journal of Clinical Oncology, 2018, 36, e18516-e18516.	1.6	0